ABUS vs MAR · P/E 5.4, rev $6.2M vs P/E 32, rev $26.19B
Arbutus Biopharma Corp (ABUS) versus Marriott International Inc (MAR) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Marriott International Inc (MAR) is a lodging company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported MAR revenue for 2025-12-31 was $26.19B. Net income was $2.60B. Revenue was up 4.3% from 2024-12-31 to 2025-12-31. MAR currently screens at market cap $76.70B and trailing P/E 31.9.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. MAR currently screens at market cap $76.70B and trailing P/E 31.9.
Not investment advice. Open the ABUS and MAR stock pages for the full models.
Not investment advice.